Impact of prior CAR T-cell treatment on graft-vs-host disease and non-relapse mortality after allogeneic transplantation
{{output}}
Background: It remains unclear whether prior chimeric antigen receptor (CAR) T-cell therapy is associated with an increased risk of graft-versus-host disease (GVHD) or non-relapse mortality (NRM) following allogeneic hematopoieti... ...
